In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech (KRYS – Research Report), with a price target of $240.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Pantginis has given his Buy rating due to a combination of factors including Krystal Biotech’s recent marketing authorization for VYJUVEK in Europe, which marks a significant regulatory milestone. This approval allows VYJUVEK to be used across E.U. member states and other European countries, with Germany set for the first launch by mid-2025. The approval supports a broad label for treating DEB patients from birth, which is expected to drive growth in the European market.
Additionally, Krystal Biotech’s HSV-1 vector platform is clinically validated, offering a promising opportunity for inhaled gene therapies. The company is advancing three early clinical programs targeting rare respiratory diseases, leveraging its gene therapy approach. The platform’s ability to overcome previous challenges in the gene therapy space, such as cargo limitations and delivery inefficiencies, further strengthens its potential. These developments, along with positive early Phase 1 findings, contribute to de-risking the company’s gene delivery platform and support the Buy rating.
In another report released on April 23, TD Cowen also maintained a Buy rating on the stock with a $208.00 price target.